The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Long-Term Treatment of Alcoholic Liver Disease with Propylthiouracil
Abstract
Propylthiouracil has been shown experimentally to protect against alcohol-induced hepatocellular necrosis in hypoxic conditions. An earlier, short-term study of patients with alcoholism and liver disease indicated clinical improvement with propylthiouracil, but the effect on mortality could not be assessed. In the present study, we investigated the effect of propylthiouracil on mortality in patients with alcoholic liver disease in a long-term, double-blind, randomized clinical trial involving 310 compliant patients who received propylthiouracil (n = 157) or placebo (n = 153) for a maximum of two years. There were no differences between the two groups in demographic and clinical characteristics and biopsy-confirmed diagnoses at randomization, or in daily urinary alcohol levels during the study. The cumulative dropout rate over two years was not significantly different (propylthiouracil group, 0.68; placebo group, 0.60). The group receiving propylthiouracil (300 mg per day) had a cumulative mortality rate half that in the group receiving placebo (0.13 vs. 0.25 [P less than 0.05] in the total sample, and 0.25 vs. 0.55 [P less than 0.03] in a subgroup of severely ill patients [propylthiouracil group, n = 56; placebo group, n = 41]). Proportional-hazards stepwise regression analyses indicated that only propylthiouracil treatment, prothrombin time, hemoglobin levels, and mean daily urinary alcohol levels significantly affected mortality. The hazards ratio for the complete group indicated that mortality in the propylthiouracil group was 0.38 (95 percent confidence interval, 0.20 to 0.83) that of the placebo group. Protection by propylthiouracil was not observed in patients with high morning urinary alcohol levels. No clinically important side effects of propylthiouracil were observed at the dose used. We conclude that the administration of propylthiouracil can reduce mortality due to alcoholic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Radioimmunoassay for Measurement of Thyroxine in Unextracted Serum*
CHOPRA, I. J. (1972) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-34-6-938 · Cited by 539
Cited by
O'Shea, R. S., Dasarathy, S., & McCullough, A. J. (2010) · Hepatology · doi:10.1002/hep.23258 · Cited by 1,077
Cytokines in Alcoholic and Nonalcoholic Steatohepatitis
Tilg, H., & Diehl, A. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432007 · Cited by 948
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.04.004 · Cited by 720
Cardiolipins and biomembrane function
Hoch, F. L. (1992) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(92)90035-9 · Cited by 595
Alcohol and the liver: 1994 update
Lieber, C. S. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90772-2 · Cited by 509
Metadata
- Authors
- Orrego, H., Blake, J. E., Blendis, L. M., Compton, K. V., & Israel, Y.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1987-12-03
- Volume
- 317
- Issue
- 23
- Pages
- 1421-1427
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2584127608
- Cited by
- 198
- References
- 1
- FWCI
- 13.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Treatment of Alcoholic Liver Disease with Propylthiouracil. https://app.cochat.ai/papers/10.1056/nejm198712033172301
- The paper
- Orrego, H., Blake, J. E., Blendis, L. M., Compton, K. V., & Israel, Y. (1987). Long-Term Treatment of Alcoholic Liver Disease with Propylthiouracil. New England Journal of Medicine. https://doi.org/10.1056/nejm198712033172301
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.